These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
383 related articles for article (PubMed ID: 17311344)
1. Obesity is associated with increased risks of prostate cancer metastasis and death after initial cancer diagnosis in middle-aged men. Gong Z; Agalliu I; Lin DW; Stanford JL; Kristal AR Cancer; 2007 Mar; 109(6):1192-202. PubMed ID: 17311344 [TBL] [Abstract][Full Text] [Related]
2. Cigarette smoking and prostate cancer-specific mortality following diagnosis in middle-aged men. Gong Z; Agalliu I; Lin DW; Stanford JL; Kristal AR Cancer Causes Control; 2008 Feb; 19(1):25-31. PubMed ID: 17906959 [TBL] [Abstract][Full Text] [Related]
3. Obesity and oncological outcome after radical prostatectomy: impact of prostate-specific antigen-based prostate cancer screening: results from the Shared Equal Access Regional Cancer Hospital and Duke Prostate Center databases. Freedland SJ; Sun L; Kane CJ; Presti JC; Terris MK; Amling CL; Moul JW; Aronson WJ BJU Int; 2008 Sep; 102(8):969-74. PubMed ID: 18691175 [TBL] [Abstract][Full Text] [Related]
4. Metastatic prostate carcinoma to bone: clinical and pathologic features associated with cancer-specific survival. Cheville JC; Tindall D; Boelter C; Jenkins R; Lohse CM; Pankratz VS; Sebo TJ; Davis B; Blute ML Cancer; 2002 Sep; 95(5):1028-36. PubMed ID: 12209687 [TBL] [Abstract][Full Text] [Related]
5. Effects of long-term exposure to traffic-related air pollution on respiratory and cardiovascular mortality in the Netherlands: the NLCS-AIR study. Brunekreef B; Beelen R; Hoek G; Schouten L; Bausch-Goldbohm S; Fischer P; Armstrong B; Hughes E; Jerrett M; van den Brandt P Res Rep Health Eff Inst; 2009 Mar; (139):5-71; discussion 73-89. PubMed ID: 19554969 [TBL] [Abstract][Full Text] [Related]
6. Pretreatment prostate-specific antigen velocity is associated with development of distant metastases and prostate cancer mortality in men treated with radiotherapy and androgen-deprivation therapy. Palma D; Tyldesley S; Pickles T; Cancer; 2008 May; 112(9):1941-8. PubMed ID: 18338814 [TBL] [Abstract][Full Text] [Related]
7. Effect of obesity on prostate-specific antigen recurrence after radiation therapy for localized prostate cancer as measured by the 2006 Radiation Therapy Oncology Group-American Society for Therapeutic Radiation and Oncology (RTOG-ASTRO) Phoenix consensus definition. Stroup SP; Cullen J; Auge BK; L'Esperance JO; Kang SK Cancer; 2007 Sep; 110(5):1003-9. PubMed ID: 17614338 [TBL] [Abstract][Full Text] [Related]
8. The impact of obesity on overall and cancer specific survival in men with prostate cancer. Davies BJ; Smaldone MC; Sadetsky N; Dall'era M; Carroll PR J Urol; 2009 Jul; 182(1):112-7; discussion 117. PubMed ID: 19447437 [TBL] [Abstract][Full Text] [Related]
9. A better prognosis for obese men with prostate cancer. Daniell HW J Urol; 1996 Jan; 155(1):220-5. PubMed ID: 7490839 [TBL] [Abstract][Full Text] [Related]
10. The ratio of oleic-to-stearic acid in the prostate predicts biochemical failure after radical prostatectomy for localized prostate cancer. Kositsawat J; Flanigan RC; Meydani M; Choi YK; Freeman VL J Urol; 2007 Dec; 178(6):2391-6; discussion 2396. PubMed ID: 17936811 [TBL] [Abstract][Full Text] [Related]
11. Body mass index, height, and prostate cancer mortality in two large cohorts of adult men in the United States. Rodriguez C; Patel AV; Calle EE; Jacobs EJ; Chao A; Thun MJ Cancer Epidemiol Biomarkers Prev; 2001 Apr; 10(4):345-53. PubMed ID: 11319175 [TBL] [Abstract][Full Text] [Related]
12. Association of body mass index with response and survival in men with metastatic prostate cancer: Southwest Oncology Group trials 8894 and 9916. Montgomery RB; Goldman B; Tangen CM; Hussain M; Petrylak DP; Page S; Klein EA; Crawford ED; J Urol; 2007 Nov; 178(5):1946-51; discussion 1951. PubMed ID: 17868721 [TBL] [Abstract][Full Text] [Related]
13. Predictors of clinical metastasis in prostate cancer patients receiving androgen deprivation therapy: results from CaPSURE. Abouassaly R; Paciorek A; Ryan CJ; Carroll PR; Klein EA Cancer; 2009 Oct; 115(19):4470-6. PubMed ID: 19637339 [TBL] [Abstract][Full Text] [Related]
14. Body mass index, weight change, and risk of prostate cancer in the Cancer Prevention Study II Nutrition Cohort. Rodriguez C; Freedland SJ; Deka A; Jacobs EJ; McCullough ML; Patel AV; Thun MJ; Calle EE Cancer Epidemiol Biomarkers Prev; 2007 Jan; 16(1):63-9. PubMed ID: 17179486 [TBL] [Abstract][Full Text] [Related]
19. Stronger association between obesity and biochemical progression after radical prostatectomy among men treated in the last 10 years. Freedland SJ; Isaacs WB; Mangold LA; Yiu SK; Grubb KA; Partin AW; Epstein JI; Walsh PC; Platz EA Clin Cancer Res; 2005 Apr; 11(8):2883-8. PubMed ID: 15837737 [TBL] [Abstract][Full Text] [Related]
20. Body mass index is not a prognostic marker for prostate-specific antigen failure and survival in Dutch men treated with brachytherapy. van Roermund JG; Hinnen KA; Battermann JJ; Witjes JA; Bosch JL; Kiemeney LA; van Vulpen M BJU Int; 2010 Jan; 105(1):42-8. PubMed ID: 19519759 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]